IBI-130 / Innovent Biologics - LARVOL DELTA

Safety and efficacy of the anti-TROP2 antibody-drug conjugate (ADC) IBI130 in patients (pts) with advanced triple-negative breast cancer (TNBC) and other solid tumors: Results from the phase 1 study. (ASCO 2025) - P1/2 | "IBI130 was well tolerated featured by superiority of hematological safety, and encouraging efficacy of IBI130 was observed in advanced TNBC, supporting its potential as a best-in-class TROP2 ADC."

Clinical • Metastases • P1 data • Breast Cancer • Dental Disorders • Interstitial Lung Disease • Oncology • Pulmonary Disease • Respiratory Diseases • Solid Tumor • Stomatitis • Triple Negative Breast Cancer

Trop2 and B7H4 bi-specific ADC with improved efficacy and safety for gynecologic cancers (AACR 2025) - "Additionally, IBI3022 shows comparable efficacy to B7H4 ADC in B7H4-positive HCC1569 cells and to Trop2 ADC IBI130 in Trop2-positive BxPC3 and HCC1954 cells. The developability profile of IBI3022 is favorable, and notably, it is well-tolerated in cynomolgus macaques at doses up to 50 mg/kg. Overall, IBI3022 represents a promising bi-specific ADC for the treatment of gynecologic cancers, offering improved efficacy and safety profiles."

Clinical • Breast Cancer • Endometrial Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor • Triple Negative Breast Cancer • TACSTD2 • VTCN1

Two innovative ADCs from Innovent Biologics have been approved for clinical use in China, targeting solid tumors! [Google translation] (163.com) - "Today (March 19), the official website of the Center for Drug Evaluation (CDE) of the China State Food and Drug Administration announced that IBI130 developed by Innovent Biologics has been approved for clinical use and is planned to be developed for unresectable locally advanced or metastatic solid tumors . A few days ago (March 13), IBI129 developed by the company has just been approved for clinical use in China and is planned to be developed for the treatment of advanced malignant solid tumors. According to the official website of Innovent, IBI130 is an antibody drug conjugate (ADC) targeting TROP2 , and IBI129 is an ADC targeting B7-H3."

New trial • Oncology • Solid Tumor

A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1/2 | N=182 | Recruiting | Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

A Phase 1/2 Clinical Study to Evaluate the Safety and Tolerability of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1/2 | N=182 | Not yet recruiting | Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Metastases • New P1/2 trial • Oncology • Solid Tumor